Two trials presented at ISTH 2020 attest to the safety and efficacy of the bispecific monoclonal antibody emicizumab as a prophylactic agent in people with haemophilia A (PwHA) with factor VIII (FVIII) inhibitors.
The overall rates of bleeding and recurrent venous thromboembolism (VTE) were low across various subgroups after 12 months of edoxaban treatment in routine clinical practice, according to a non-interventional, post-authorization safety study of edoxaban — ETNA-VTE* presented during the ISTH 2020 Meeting.
Treatment with apixaban led to a significantly reduced risk of venous thromboembolism (VTE) among ambulatory cancer patients who were undergoing chemotherapy, according to two post hoc analyses of the AVERT* trial presented at the ISTH 2020 Meeting.
Thrombotic complications are rife among in-hospital patients with COVID-19, with patients in the ICU particularly at risk compared with those in the general wards, a study released at the ISTH 2020 Meeting has shown.
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.